Solid State Pharma is a privately held solid state and crystallization engineering company that was founded in 2014. We are a recognized global leader in the delivery of crystallization engineering services, including screening and selection of polymorphs, co-crystals, salts, and crystallization process development and optimization.
We partner with pharmaceutical and natural product companies to add value to every process, by understanding the solid state of their drug candidates, and developing processes that will lead to optimal physical properties, morphology and particle size distribution.
Our full suite of services includes comprehensive understanding of solid state of active pharmaceutical ingredients (API) and the regulatory requirements that are integral to effective development, innovation and manufacturing. Solid State Pharma’s expertise helps to enhance the development of drug candidates and commercial products by enabling better quality products and a faster route to market.
We are passionate scientists who specialize in both early and late stage pharmaceutical development. Our technical staff have successfully completed more than 500 hands-on projects and published more than 100 journal articles, patents, and patent applications on crystallization engineering and solid form science.
We believe that science has a duty to benefit humanity and we apply our knowledge and the latest technology to help our clients develop pharmaceutical products that will improve the lives of patients. We are mavericks; always looking for better ways to apply our ingenuity to solve complex problems. We are realists; who share in the success of our clients and take responsibility for our work by applying rigorous analysis and retaining an objective perspective. Above all, we are people who enjoy collaborating with others and learning from them; we are constantly growing and improving.
Solid State Pharma was founded on the basis of human ingenuity by Dr. Mahmoud Mirmehrabi in 2014. Early on, Mahmoud had a passion for this science. He received his PhD from The University of Western Ontario in Chemical Engineering with his thesis being titled “Characterization and Control of Polymorphism in Pharmaceutical Solids”. He has published more than 60 publications, patents and patent applications, and 20 national and international presentations.
After 15 years of industry experience working at several large pharma companies, including Apotex, Wyeth/Pfizer, and Johnson Matthey, he saw an opportunity in the industry for a science driven company in this niche field. He used his knowledge and experience to build a company focused on unleashing the ingenuity of other passionate and talented people.
Today, we are lucky to have a company filled with talented people and clients across the globe. Our approach to all client interactions is governed by our commitment to integrity and quality. We strive to deliver clear reliable results to our clients and to exceed their expectations at every stage of our collaboration. We are proud that the same values the company was originally built on continue to be massive components of our day to day operations.